These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28112977)

  • 1. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R
    Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
    Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
    Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
    Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
    Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
    PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.
    Barley K; Tindle S; Bagiella E; Jagannath S; Chari A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):541-5. PubMed ID: 26119495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
    Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
    González-Calle V; Cerdá S; Labrador J; Sobejano E; González-Mena B; Aguilera C; Ocio EM; Vidriales MB; Puig N; Gutiérrez NC; García-Sanz R; Alonso JM; López R; Aguilar C; de Coca AG; Hernández R; Hernández JM; Escalante F; Mateos MV
    Haematologica; 2017 May; 102(5):922-931. PubMed ID: 28126960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.
    Pratt G; Mead GP; Godfrey KR; Hu Y; Evans ND; Chappell MJ; Lovell R; Bradwell AR
    Leuk Lymphoma; 2006 Jan; 47(1):21-8. PubMed ID: 16321823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
    El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
    Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation.
    Strasser-Weippl K; Ludwig H
    Leuk Lymphoma; 2014 Nov; 55(11):2520-4. PubMed ID: 24512320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
    Kim C; Lee HS; Min CK; Lee JJ; Kim K; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC
    Korean J Intern Med; 2015 Sep; 30(5):675-83. PubMed ID: 26354062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
    Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
    Mösbauer U; Ayuk F; Schieder H; Lioznov M; Zander AR; Kröger N
    Haematologica; 2007 Feb; 92(2):275-6. PubMed ID: 17296589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
    Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
    Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.